590 related articles for article (PubMed ID: 29534307)
1. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
J Gastroenterol; 2019 Feb; 54(2):182-193. PubMed ID: 30136216
[TBL] [Abstract][Full Text] [Related]
3. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
[TBL] [Abstract][Full Text] [Related]
4. Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance.
Lee HW; Lee JI; Kim S; Kim S; Chang HY; Lee KS
BMC Gastroenterol; 2020 Apr; 20(1):113. PubMed ID: 32305059
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: a longitudinal follow-up study.
Fung J; Seto WK; Wong DK; Lai CL; Yuen MF
Liver Int; 2015 Mar; 35(3):854-9. PubMed ID: 24840542
[TBL] [Abstract][Full Text] [Related]
6. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma.
Liu J; Yang HI; Lee MH; Lu SN; Jen CL; Batrla-Utermann R; Wang LY; You SL; Hsiao CK; Chen PJ; Chen CJ;
Gut; 2014 Oct; 63(10):1648-57. PubMed ID: 24225939
[TBL] [Abstract][Full Text] [Related]
7. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance.
Kim GA; Lee HC; Kim MJ; Ha Y; Park EJ; An J; Lee D; Shim JH; Kim KM; Lim YS
J Hepatol; 2015 May; 62(5):1092-9. PubMed ID: 25445399
[TBL] [Abstract][Full Text] [Related]
8. Clinical features of HBsAg seroclearance in hepatitis B virus carriers in South Korea: A retrospective longitudinal study.
Park YM; Lee SG
World J Gastroenterol; 2016 Nov; 22(44):9836-9843. PubMed ID: 27956808
[TBL] [Abstract][Full Text] [Related]
9. Natural history of chronic hepatitis B REVEALed.
Chen CJ; Yang HI
J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
[TBL] [Abstract][Full Text] [Related]
10. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection.
Liu J; Lee MH; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; Wang LY; You SL; Hsiao CK; Yang HI; Chen CJ
J Hepatol; 2013 May; 58(5):853-60. PubMed ID: 23246508
[TBL] [Abstract][Full Text] [Related]
11. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
Seto WK; Wong DK; Fung J; Huang FY; Lai CL; Yuen MF
Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
[TBL] [Abstract][Full Text] [Related]
12. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study.
Liu J; Yang HI; Lee MH; Lu SN; Jen CL; Wang LY; You SL; Iloeje UH; Chen CJ;
Gastroenterology; 2010 Aug; 139(2):474-82. PubMed ID: 20434450
[TBL] [Abstract][Full Text] [Related]
13. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients.
Chan HL; Wong GL; Tse CH; Chan HY; Wong VW
J Infect Dis; 2011 Aug; 204(3):408-14. PubMed ID: 21742839
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B surface antigen seroclearance in patients with chronic hepatitis B infection: a clinical study.
Ruan P; Xu SY; Zhou BP; Huang J; Gong ZJ
J Int Med Res; 2013 Oct; 41(5):1732-9. PubMed ID: 23908397
[TBL] [Abstract][Full Text] [Related]
15. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.
Lee MH; Yang HI; Liu J; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; You SL; Wang LY; Chen CJ;
Hepatology; 2013 Aug; 58(2):546-54. PubMed ID: 23504622
[TBL] [Abstract][Full Text] [Related]
16. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load.
Tseng TC; Liu CJ; Yang HC; Su TH; Wang CC; Chen CL; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
Gastroenterology; 2012 May; 142(5):1140-1149.e3; quiz e13-4. PubMed ID: 22333950
[TBL] [Abstract][Full Text] [Related]
17. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
Yip TC; Chan HL; Wong VW; Tse YK; Lam KL; Wong GL
J Hepatol; 2017 Nov; 67(5):902-908. PubMed ID: 28652084
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B surface antigen seroclearance: Relationship to hepatitis B e-antigen seroclearance and hepatitis B e-antigen-negative hepatitis.
Fung J; Wong DK; Seto WK; Kopaniszen M; Lai CL; Yuen MF
Am J Gastroenterol; 2014 Nov; 109(11):1764-70. PubMed ID: 25244963
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of children with postnatal immunoprophylaxis failure who were infected with hepatitis B virus surface antigen gene mutant.
Hsu HY; Chang MH; Ni YH; Jeng YM; Chiang CL; Chen HL; Wu JF; Chen PJ
J Infect Dis; 2013 Apr; 207(7):1047-57. PubMed ID: 23300165
[TBL] [Abstract][Full Text] [Related]
20. What can we learn from hepatitis B virus clinical cohorts?
Lin CL; Tseng TC; Kao JH
Liver Int; 2015 Jan; 35 Suppl 1():91-9. PubMed ID: 25529093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
